Skip to main content

Detail

Peter Matzneller
Dr. Peter Matzneller

Department of Clinical Pharmacology
Position: Doctor-in-training

T +43 1 40400 29810
peter.matzneller@meduniwien.ac.at

Further Information

Keywords

Anti-Infective Agents; Microbiology; Pharmacokinetics

Research interests

My main research focus is to investigate pharmacokinetics (PK) and pharmacodynamics (PD) of anti-infective agents.

We perform clinical studies in healthy volunteers and patients using microdialysis, a technique which permits direct measurement of unbound drugs in virtually every human tissue. Soft tissue (e.g. muscle and subcutaneous adipose tissue) PK and plasma protein binding can thus be easily quantified in vivo. Both values are essential as a basis for correct dosage of e.g. an antibiotic and can otherwise only be estimated from PK of total drug in plasma and potentially unreliable in vitro techniques.

In addition, I am involved in microbiological experiments to assess activity of antimicrobial and antifungal drugs in vitro (MIC determination, time-kill curves) in the microbiological lab of the Department of Clinical Pharmacology.

Techniques, methods & infrastructure

  • in vivo: microdialysis, sampling of bronchoalveolar lavage and alveolar macrophages, impact of drugs on inflammation in human endotoxemia
  • in vitro: broth microdilution, time-kill experiments

Selected publications

  1. Matzneller, P. et al., 2017. Colistin Reduces LPS-Triggered Inflammation in a Human Sepsis Model In Vivo: A Randomized Controlled Trial. Clinical Pharmacology & Therapeutics, 101(6), pp.773-781. Available at: http://dx.doi.org/10.1002/cpt.582.
  2. Matzneller, P. et al., 2016. Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study. Journal of Antimicrobial Chemotherapy, 71(11), pp.3179-3184. Available at: http://dx.doi.org/10.1093/jac/dkw269.
  3. Matzneller, P. et al., 2016. Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil. Antimicrobial Agents and Chemotherapy, 60(6), pp.3617-3625. Available at: http://dx.doi.org/10.1128/AAC.00097-16.